What Role for Angiogenesis in Childhood Acute Lymphoblastic Leukaemia?

• Published in: Advances in Hematology Vol. 2011; no. 2011; pp. 62 - 69
• Main Authors: Gouel, F., Schneider, P., Vasse, M., Vannier, J. P., Legrand, E., Dubus, I.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 2011; Hindawi Puplishing Corporation; Hindawi Publishing Corporation; Hindawi Limited
• Subjects: Review
• ISSN: 1687-9104; 1687-9112
• DOI: 10.1155/2011/274628

The role of angiogenesis in acute leukaemia has been discussed since the cloning of the gene of vascular endothelial growth factor (VEGF) from the acute myelogenous leukemia cell line (HL60) and, thereafter, when the first studies reported increased bone marrow vascularity and elevation of angiogenic cytokines in acute lymphoblastic leukaemia (ALL). VEGF and basic fibroblast growth factor (bFGF) are the major proangiogenic cytokines that have been studied, and evaluation of their prognostic impact in childhood ALL has been reported in several studies, though with controversial results. The antiangiogenic response, contributing to the angiogenic balance, has scarcely been reported. The origin of the factors, their prognostic value, and their relevance as good markers of what really happens in the bone marrow are discussed in this paper. The place of antiangiogenic drugs in ALL has to be defined in the global treatment strategy.